Magnetar Financial’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-834,390
Closed -$49M – 524
2023
Q4
$49M Buy
+834,390
New +$46.9M 1.24% 24
2023
Q2
– Sell
-21,875
Closed -$813K – 688
2023
Q1
$813K Buy
+21,875
New +$984K 0.02% 412
2022
Q3
– Sell
-7,807
Closed -$524K – 1663
2022
Q2
$524K Sell
7,807
-6,098
-44% -$388K 0.01% 1134
2022
Q1
$1.14M Buy
+13,905
New +$1.42M 0.01% 777
2021
Q3
– Sell
-1,783
Closed -$288K – 1570
2021
Q2
$288K Buy
+1,783
New +$286K ﹤0.01% 1038
2021
Q1
– Sell
-3,719
Closed -$817K – 1221
2020
Q4
$817K Buy
+3,719
New +$804K 0.01% 502
2020
Q1
– Sell
-1,554
Closed -$200K – 678
2019
Q4
$200K Buy
+1,554
New +$150K ﹤0.01% 497

Other funds holding MRTX

Magnetar Financial's MRTX Position: Q1 2024 in Review

Magnetar Financial sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 834,390 shares — an estimated $49M sold.

Magnetar Financial first reported a position in MRTX in Q4 2019 and held it in 7 quarters. The position peaked at $49M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Magnetar Financial reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Magnetar Financial sold 834,390 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $49M.
  • Magnetar Financial first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
  • Magnetar Financial's Mirati Therapeutics, Inc. Common Stock position peaked at $49M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Magnetar Financial's 13F filing for Q1 2024, filed 15 May 2024.